for Celator Pharmaceuticals 17734634211

British Business Secretary PeterMandelson said he was determined to ensure car making remainedan important part of Britain's manufacturing industry. "The economy will improve andwhen it does Nissan will need these workers again." Prime Minister Gordon Brown is set to hold a so-called "jobssummit" on Monday when he will meet business leaders at DowningStreet to try to find ways to staunch the flow of job losses. Brown has pledged to create 100,000 jobs via a public worksprogramme. Some economists have forecast unemployment could climb toalmost three million by the end of 2009 and the issue is movingup the political agenda ahead of an election due by May 2010. RESTRUCTURE REQUIRED Mandelson said the car industry globally was robust butneeded serious restructuring in order to compete once marketconditions eased.

He said the British car industry had not asked for agovernment bailout but talks were continuing to help theindustry secure a viable future.He said any assistance to the beleaguered sector in the U.S.should be conditional. "It would be a great mistake in my view if the Americangovernment were simply to hand out vast subsidies withoutensuring that the industry itself brought about therestructuring and the consolidation that it really needs toensure its success in the future and that goes not just for theindustry in the U.S but also in Europe," he said. Nissan said the measures would safeguard the long-termviability of the Sunderland plant, where about 5,000 people areemployed producing models including the Micra, Note and Qashqai. New vehicle registrations in Britain fell 11.3 percent lastyear compared with 2007, industry group the Society of MotorTraders and Manufacturers said on Wednesday. ID:nLAK000321 (Editing by Keith Weir and Dan Lalor) Stocks. PRINCETON, N.J., Jan. 8 /PRNewswire/ Celator Pharmaceuticals todayannounced that Scott Jackson, chief executive officer, is scheduled to presentat the Biotech Showcase 2009 in San Francisco.Mr.

Jackson will provide acorporate overview and an update on the company's clinical developmentprograms.The presentation will be held on Wednesday, January 14, 2009 at10:30AM PST in Room A of the Marines' Memorial Club & Hotel.About CelatorCelator(R) Pharmaceuticals, Inc., with locations in Princeton, NJ, andVancouver, BC, is a privately held pharmaceutical company developing new andmore effective therapies to treat cancer.CombiPlex(R), the company's drugratio technology platform, represents a novel approach that identifies molarratios of drugs that will deliver a synergistic benefit, locks the desiredratio in a drug delivery vehicle that maintains the ratio in patients with thegoal of improving clinical outcomes.The company pipeline includes: CPX-1 (aliposomal formulation of irinotecan:floxuridine), currently in Phase 2 inpatients with colorectal cancer; CPX-351 (a liposomal formulation ofcytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloidleukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), apreclinical stage compound; and multiple research programs.Based on theapplications of CombiPlex, Celator is positioned to advance a broad pipelineof combination therapies involving both previously approved and novel drugagents. for Celator Pharmaceuticals, 1-773-463-4211,. If the University of Notre Dame fires head football coach Charlie Weis, his replacement will demand the university loweracademic standards for football players. It will be written into his contract.If Notre Dame has decided to pursue an experienced college coach with national championship or BCS-bowl credentials, they will have to bend on the issue of academic eligibility and course requirements.High-powered college football coaches are well aware of thedifficulties in winning and the demands of winning at a school like Notre Dame.